JP2024540322A - SARS-CoV-2によって引き起こされる疾患の予防及び処置に使用するための免疫原性構築物及びワクチン - Google Patents

SARS-CoV-2によって引き起こされる疾患の予防及び処置に使用するための免疫原性構築物及びワクチン Download PDF

Info

Publication number
JP2024540322A
JP2024540322A JP2024526682A JP2024526682A JP2024540322A JP 2024540322 A JP2024540322 A JP 2024540322A JP 2024526682 A JP2024526682 A JP 2024526682A JP 2024526682 A JP2024526682 A JP 2024526682A JP 2024540322 A JP2024540322 A JP 2024540322A
Authority
JP
Japan
Prior art keywords
seq
amino acid
unit
acid sequence
cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024526682A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024540322A5 (cg-RX-API-DMAC10.html
Inventor
エーベルト ピーター
フレードリクセン アグネーテ
クリンガー マーク
ノルハイム グンステイン
オズボーン エドワード
セケルヤ モニカ
スナイダー トーマス
ストゥブスル エリザベス
Original Assignee
ナイコード セラピューティクス アルメン アクスイェ セルスカプ
アダプティブ バイオテクノロジーズ コーポレイション
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ナイコード セラピューティクス アルメン アクスイェ セルスカプ, アダプティブ バイオテクノロジーズ コーポレイション filed Critical ナイコード セラピューティクス アルメン アクスイェ セルスカプ
Publication of JP2024540322A publication Critical patent/JP2024540322A/ja
Publication of JP2024540322A5 publication Critical patent/JP2024540322A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/215—Coronaviridae, e.g. avian infectious bronchitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/08—RNA viruses
    • C07K14/165—Coronaviridae, e.g. avian infectious bronchitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20051—Methods of production or purification of viral material
    • C12N2770/20052—Methods of production or purification of viral material relating to complementing cells and packaging systems for producing virus or viral particles
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/36011—Togaviridae
    • C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
    • C12N2770/36122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pulmonology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
JP2024526682A 2021-11-03 2022-11-03 SARS-CoV-2によって引き起こされる疾患の予防及び処置に使用するための免疫原性構築物及びワクチン Pending JP2024540322A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202163275015P 2021-11-03 2021-11-03
US63/275,015 2021-11-03
US202263377087P 2022-09-26 2022-09-26
US63/377,087 2022-09-26
PCT/EP2022/080679 WO2023079001A1 (en) 2021-11-03 2022-11-03 Immunogenic constructs and vaccines for use in the prophylactic and therapeutic treatment of diseases caused by sars-cov-2

Publications (2)

Publication Number Publication Date
JP2024540322A true JP2024540322A (ja) 2024-10-31
JP2024540322A5 JP2024540322A5 (cg-RX-API-DMAC10.html) 2025-11-11

Family

ID=84365420

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024526682A Pending JP2024540322A (ja) 2021-11-03 2022-11-03 SARS-CoV-2によって引き起こされる疾患の予防及び処置に使用するための免疫原性構築物及びワクチン

Country Status (9)

Country Link
US (1) US20250049910A1 (cg-RX-API-DMAC10.html)
EP (1) EP4426344A1 (cg-RX-API-DMAC10.html)
JP (1) JP2024540322A (cg-RX-API-DMAC10.html)
KR (1) KR20240110821A (cg-RX-API-DMAC10.html)
AU (1) AU2022381515A1 (cg-RX-API-DMAC10.html)
CA (1) CA3235174A1 (cg-RX-API-DMAC10.html)
IL (1) IL312539A (cg-RX-API-DMAC10.html)
MX (1) MX2024005408A (cg-RX-API-DMAC10.html)
WO (1) WO2023079001A1 (cg-RX-API-DMAC10.html)

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2004215489B2 (en) 2003-02-25 2010-07-15 Nykode Therapeutics ASA Modified antibody
WO2011161244A1 (en) 2010-06-25 2011-12-29 Vaccibody As Homodimeric protein constructs
EP3533462A1 (en) 2011-12-21 2019-09-04 Vaccibody AS Vaccines against hpv
JP2019505512A (ja) 2016-01-08 2019-02-28 バッシボディ アクスイェ セルスカプ 治療用抗癌ネオエピトープワクチン
CN113631185A (zh) 2019-02-27 2021-11-09 尼克塔治疗公司 用于治疗癌症的免疫治疗组合
PH12022552164A1 (en) * 2020-02-19 2023-11-29 United Biomedical Inc Designer peptides and proteins for the detection, prevention and treatment of coronavirus disease, 2019 (covid-19)
US20230218741A1 (en) * 2020-03-31 2023-07-13 The Children's Hospital Of Philadelphia Sars-cov-2 vaccines for population-scale immunity

Also Published As

Publication number Publication date
WO2023079001A1 (en) 2023-05-11
AU2022381515A1 (en) 2024-05-09
CA3235174A1 (en) 2023-05-11
IL312539A (en) 2024-07-01
US20250049910A1 (en) 2025-02-13
KR20240110821A (ko) 2024-07-16
EP4426344A1 (en) 2024-09-11
MX2024005408A (es) 2024-08-06

Similar Documents

Publication Publication Date Title
JP7535489B2 (ja) 治療用抗癌ネオエピトープワクチン
JP2023524054A (ja) ベータコロナウイルスの予防と治療
TWI767275B (zh) Hiv疫苗以及製造及使用方法
KR20220154121A (ko) 코로나바이러스 면역원성 조성물 및 이의 용도
US20210283242A1 (en) Immune-mediated coronavirus treatments
CN111533812B (zh) 针对sars-cov-2病毒的dna疫苗及其用途
KR20160091350A (ko) 중동 호흡기 증후군 코로나바이러스(MERS-CoV) 백신
US20130139274A1 (en) B-cell stimulating fusion proteins of an antigen with baff or april
WO2013003579A1 (en) Cytotoxic t-lymphocyte-inducing immunogens for prevention, treatment, and diagnosis of dengue virus infection
WO2022071513A1 (ja) SARS-CoV-2に対する改良型DNAワクチン
KR20240163165A (ko) 에피토프의 조합과 그의 용도, 백신 구조물, 면역 반응의 유도 방법 에피토프의 식별 방법
WO2015175361A1 (en) Dengue virus specific multiple hla binding t cell epitopes for the use of universal vaccine development
KR20180101529A (ko) 인플루엔자 백신접종을 위한 방법 및 조성물
US20250339509A1 (en) Immunogenic constructs and vaccines for use in the prophylactic and therapeutic treatment of infectious diseases
WO2022238363A1 (en) Immunogenic constructs and vaccines for use in the prophylactic and therapeutic treatment of infectious diseases
JP5901084B2 (ja) ペプチドアジュバント
US20250222085A1 (en) Co-expression of constructs and immunostimulatory compounds
US20250049910A1 (en) Immunogenic Constructs And Vaccines For Use In The Prophylactic And Therapeutic Treatment Of Diseases Caused By SARS-CoV-2
CN118742321A (zh) 用于预防性和治疗性治疗由SARS-CoV-2引起的疾病的免疫原性构建体和疫苗
US20220023412A1 (en) Compositions Useful in Both Homologous And Heterologous Vaccine Regimens
JP2018528974A (ja) ヒトおよびネコにおけるワクチンのためのhiv、sivおよびfivの交差反応性t細胞エピトープ
WO2022238381A2 (en) Immunotherapy constructs for treatment of disease
CA3157810A1 (en) Vaccines against coronaviruses

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20251031

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20251031